Summary by Futu AI
Biodexa Pharmaceuticals PLC, a company with principal executive offices in Cardiff, United Kingdom, has been the subject of an amended filing with the U.S. Securities and Exchange Commission (SEC) on February 14, 2024. The amendment, known as Schedule 13G/A, indicates that several reporting persons, including Ionic Ventures LLC, Ionic Management LLC, Brendan O'Neil, and Keith Coulston, have collectively ceased to be the beneficial owners of more than five percent of the company's outstanding American Depositary Shares (ADSs). The filing, which serves as an exit filing for the reporting persons, updates their beneficial ownership information and amends previous disclosures. The ADSs in question represent 400 ordinary shares each, with a nominal value of £0.001 per share. The reporting persons had shared voting...Show More